Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2
account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the
results obtained by surgery alone or surgery followed by chemotherapy (CT) and/or
radiotherapy (RT) are insufficient. The neoadjuvant approach was tested, in randomized tests
of exclusive CT, or in noncomparative tests of RT-CT.